Home › Compare › CLBS vs VICI

CLBS vs VICI: Dividend Comparison 2026

CLBS yields 131.33% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLBS wins by $12.03M in total portfolio value
10 years
CLBS
CLBS
● Live price
131.33%
Share price
$0.43
Annual div
$0.56
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12.99M
Annual income
$5,201,713.69
Full CLBS calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — CLBS vs VICI

📍 CLBS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLBSVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLBS + VICI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CLBS pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLBS
Annual income on $10K today (after 15% tax)
$11,163.23/yr
After 10yr DRIP, annual income (after tax)
$4,421,456.64/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, CLBS beats the other by $3,905,186.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLBS + VICI for your $10,000?

CLBS: 50%VICI: 50%
100% VICI50/50100% CLBS
Portfolio after 10yr
$6.98M
Annual income
$2,904,544.90/yr
Blended yield
41.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CLBS
No analyst data
Altman Z
-42.9
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLBS buys
0
VICI buys
0
No recent congressional trades found for CLBS or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLBSVICI
Forward yield131.33% ✓6.52%
Annual dividend / share$0.56$1.78 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3% ✓
Portfolio after 10y$12.99M$966.2K ✓
Annual income after 10y$5,201,713.69 ✓$607,376.13
Total dividends collected$11.90M$926.2K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CLBS vs VICI ($10,000, DRIP)

YearCLBS PortfolioCLBS Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$23,833$13,133.21$11,361$941.49+$12.5K → CLBS
2$54,754$29,252.94$13,320$1,481.32+$41.4K → CLBS
3$121,396$62,809.15$16,284$2,405.01+$105.1K → CLBS
4$260,039$130,144.39$21,040$4,071.78+$239.0K → CLBS
5$538,781$260,539.45$29,209$7,285.49+$509.6K → CLBS
6$1,080,999$504,503.28$44,443$14,006.51+$1.04M → CLBS
7$2,102,673$946,004.75$75,822$29,512.55+$2.03M → CLBS
8$3,969,574$1,719,713.85$148,733$69,726.75+$3.82M → CLBS
9$7,281,647$3,034,202.37$344,394$189,413.75+$6.94M → CLBS
10$12,993,076$5,201,713.69$966,234$607,376.13+$12.03M → CLBS

CLBS vs VICI: Complete Analysis 2026

CLBS — Stock

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Full CLBS Calculator →

VICI — REIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CLBS vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLBS vs SCHDCLBS vs JEPICLBS vs OCLBS vs KOCLBS vs MAINCLBS vs NNNCLBS vs EPRTCLBS vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.